Navigation Links
Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS
Date:7/28/2009

BELGRADE, SERBIA, July 28 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com, Slavica Bio Chem Division (Slavica) intends to re release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in Europe only, several years ago.

Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites www.slavicabiotech.com and www.htdsmedical.com. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.

In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanstvo/Biografije/LjubisavRakic.pdf ) accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian Academy of Sciences and Arts in charge for natural sciences."

Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division) http://www.mellowhope.com/en/main.asp. This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.

Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from Germany where she finished her PhD studies and got her PhD diploma, and now is a part of our team. Also, she is an assistant professor at the State University Novi Pazar, she speaks: English -professionally, CAE certificate, grades A, German - upper intermediate level, French - basics and is an enthusiastic young scientist with a lot of fresh and original ideas.

In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in China, and having our North American office and our advisors disseminate timely updates to the HTDS followers, shareholders and the medical professionals."

The company intends to provide many updates on the work and HTDS activities on a timely basis.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: corporate@HTDScorporation.com

CONTACT: corporate@HTDScorporation.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: